MECP2 and breast cancer: Recently, Zhou et al. have documented that Linc-ROR decreases BC cell sensitivity to mTOR inhibitor rapamycin by sponging miR-194-3p and releasing methyl CpG-binding protein 2 (MECP2) 91.